November 24, 2016 - By Richard Conner · 0 Comments
The stock of Atricure Incorporated (NASDAQ:ATRC) registered an increase of 22.47% in short interest. ATRC’s total short interest was 3.22M shares in November as published by FINRA. Its up 22.47% from 2.63M shares, reported previously. With 421,200 shares average volume, it will take short sellers 8 days to cover their ATRC’s short positions. The short interest to Atricure Incorporated’s float is 11.67%. The stock increased 0.21% or $0.04 on November 23, hitting $19.42. About 205,545 shares traded hands. AtriCure Inc. (NASDAQ:ATRC) has risen 16.99% since April 22, 2016 and is uptrending. It has outperformed by 11.58% the S&P500.
AtriCure, Inc. is a medical device company providing atrial fibrillation solutions. The company has a market cap of $638.93 million. The Company’s segment develops, makes, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It currently has negative earnings. The Firm has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Insitutional Activity: The institutional sentiment increased to 1.88 in 2016 Q2. Its up 0.92, from 0.96 in 2016Q1. The ratio improved, as 15 funds sold all AtriCure Inc. shares owned while 31 reduced positions. 5 funds bought stakes while 39 increased positions. They now own 24.21 million shares or 10.01% less from 26.90 million shares in 2016Q1.
Vident Invest Advisory Llc has 44,488 shares for 0.09% of their US portfolio. Rothschild Capital Prns Llc has 243,740 shares for 1.82% of their US portfolio. Northern Tru Corp last reported 0% of its portfolio in the stock. Blair William Il holds 100,185 shares or 0.01% of its portfolio. Emerald Mutual Fund Advisers Trust owns 522,174 shares or 0.41% of their US portfolio. Amer Interest Gru Incorporated has 18,093 shares for 0% of their US portfolio. Metropolitan Life Insur accumulated 23,721 shares or 0% of the stock. Paradigm Management Ny has invested 0.57% of its portfolio in AtriCure Inc. (NASDAQ:ATRC). D E Shaw And Comm has 65,975 shares for 0% of their US portfolio. Kopp Invest Advisors Ltd Liability has 1.41% invested in the company for 187,226 shares. Ubs Asset Americas has 12,100 shares for 0% of their US portfolio. Blackrock Advsrs Ltd Liability Corp accumulated 14,654 shares or 0% of the stock. Adage Ptnrs Gru Limited Liability Co last reported 250,000 shares in the company. Essex Invest Mngmt Co Lc reported 79,076 shares or 0.19% of all its holdings. Moreover, Blackrock Institutional Trust Na has 0% invested in AtriCure Inc. (NASDAQ:ATRC) for 738,010 shares.
Insider Transactions: Since August 16, 2016, the stock had 0 buys, and 4 insider sales for $377,984 net activity. Shares for $95,580 were sold by Krell Elizabeth D. Seith Douglas J also sold $9,104 worth of AtriCure Inc. (NASDAQ:ATRC) on Monday, November 14.
Out of 7 analysts covering Atricure Inc. (NASDAQ:ATRC), 6 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 86% are positive. Atricure Inc. has been the topic of 13 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The stock has “Sell” rating given by UBS on Tuesday, September 22. Northland Capital initiated AtriCure Inc. (NASDAQ:ATRC) on Tuesday, March 29 with “Outperform” rating. Needham maintained AtriCure Inc. (NASDAQ:ATRC) rating on Wednesday, October 28. Needham has “Buy” rating and $23 price target. Needham maintained AtriCure Inc. (NASDAQ:ATRC) on Tuesday, August 4 with “Buy” rating. The stock has “Buy” rating given by Canaccord Genuity on Tuesday, October 6. The company was maintained on Wednesday, July 29 by Needham. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, August 5. The company was initiated on Friday, August 7 by BTIG Research. The firm earned “Buy” rating on Tuesday, July 28 by Dougherty & Company. The company was maintained on Tuesday, October 6 by Needham.
AtriCure, Inc., incorporated on October 31, 2000, is a medical device firm providing atrial fibrillation (Afib) solutions. The Company’s segment develops, makes, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Firm has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. The Firm offers various minimally invasive ablation devices and access tools to facilitate less invasive cardiac and thoracic surgery. The Company’s cryoICE cryosurgery product line offers various cryoablation devices. The Company’s AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). The Company’s products are utilized by cardiothoracic surgeons during both open-heart and minimally invasive procedures, either on a concomitant or sole-therapy basis. The Company’s Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair. The Firm has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner